Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy
作者： Moulay A. Alaoui-Jamali , Devanand Pinto
DOI: 10.1007/978-1-59745-169-7_3
关键词:
摘要: Protein tyrosine kinases (PTKs) and their substrates are emerging as attractive therapeutic targets potential biomarkers for molecular classifications, prediction of clinical outcome monitoring response to cancer treatments. The exciting move toward kinase-targeted therapy has brought new technical challenges in profiling protein kinase genes proteins surrogate biomarkers, particularly light data correlating specific mutations PTKs with either sensitivity or resistance targeted therapy. This chapter discusses the impact on conformation, phosphorylation, drug utility proteomic technology mine phosphoproteome PTK therapies.
springer.com
springerlink.com参考文章(82)
Steven K. Hanks, Anne Marie Quinn, [2] Protein kinase catalytic domain sequence database: Identification of conserved features of primary structure and classification of family members Methods in Enzymology. ,vol. 200, pp. 38- 62 ,(1991) , 10.1016/0076-6879(91)00126-H
U. Novak, A. W. Burgess, A. H. Kaye, L. T. Malden, Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. Cancer Research. ,vol. 48, pp. 2711- 2714 ,(1988)
Toshimasa Yamauchi, Kohjiro Ueki, Kazuyuki Tobe, Hiroyuki Tamemoto, Nobuo Sekine, Mitsufumi Wada, Masaru Honjo, Michio Takahashi, Tokiharu Takahashi, Hisamaru Hirai, Toshio Tushima, Yasuo Akanuma, Toshiro Fujita, Issei Komuro, Yoshio Yazaki, Takashi Kadowaki, Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone Nature. ,vol. 390, pp. 91- 96 ,(1997) , 10.1038/36369
Peter Blume-Jensen, Tony Hunter, Oncogenic kinase signalling. Nature. ,vol. 411, pp. 355- 365 ,(2001) , 10.1038/35077225
J. D. York, SIGNAL TRANSDUCTION: Unexpected Mediators of Protein Phosphorylation Science. ,vol. 306, pp. 2053- 2055 ,(2004) , 10.1126/SCIENCE.1107225
Michael Deininger, Resistance to imatinib: mechanisms and management. Journal of The National Comprehensive Cancer Network. ,vol. 3, pp. 757- 768 ,(2005) , 10.6004/JNCCN.2005.0045
Yosef Yarden, Mark X. Sliwkowski, Untangling the ErbB signalling network Nature Reviews Molecular Cell Biology. ,vol. 2, pp. 127- 137 ,(2001) , 10.1038/35052073
Nikolas von Bubnoff, Folker Schneller, Christian Peschel, Justus Duyster, BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study The Lancet. ,vol. 359, pp. 487- 491 ,(2002) , 10.1016/S0140-6736(02)07679-1
Michael J Morin, From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene. ,vol. 19, pp. 6574- 6583 ,(2000) , 10.1038/SJ.ONC.1204102
Catherine Roche-Lestienne, Claude Preudhomme, Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Seminars in Hematology. ,vol. 40, pp. 80- 82 ,(2003) , 10.1053/SHEM.2003.50046